CELL INTELLIGENCE · 肿瘤细胞治疗研究

骨肉瘤肿瘤免疫微环境重塑与病理性骨折风险关联的研究进展

Advances in the association between tumor immune microenvironment remodeling in osteosarcoma and the risk of pathological fractures.

骨肉瘤的基因免疫治疗：从溶瘤载体到工程化免疫细胞

Gene-based immunotherapy in osteosarcoma: from oncolytic vectors to engineered immune cells.

儿童软组织肉瘤中的 NK 细胞：一项系统综述

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review.

儿童骨肉瘤的免疫治疗：当前进展与未来方向

Immunotherapy in pediatric bone sarcomas: Current progress and future directions.

骨肉瘤中的代谢-免疫串扰：机制与治疗机会

Metabolic-immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities.

犬骨肉瘤的空间转录组图谱揭示与生存相关的免疫微环境特征

Spatial transcriptomic mapping of canine osteosarcoma reveals immune microenvironment features linked to survival.

YB-1 抑制可抑制骨肉瘤生长并逆转肿瘤免疫抑制

YB-1 inhibition suppresses osteosarcoma growth and reverses tumor immunosuppression.

开发并评价一种可吸入纳米乳系统以增强 NK 细胞对抗骨肉瘤肺转移的功能

Development and evaluation of an inhalable nanoemulsion system for enhancing NK cell function against osteosarcoma pulmonary metastases.

本研究建立了一种新型可吸入纳米乳平台，可显著恢复 NK 细胞对抗肺转移性骨肉瘤的功能。

衰老通过免疫功能障碍和肿瘤细胞重编程重塑骨肉瘤生态系统

Aging reshapes the osteosarcoma ecosystem through immune dysfunction and tumor cell reprogramming.

我们的研究揭示了骨肉瘤中免疫和肿瘤内在区室由衰老驱动的协同重塑，其特征为免疫功能障碍和恶性细胞重编程。这些发现为老年 OS 患者中观察到的较差预后提供了机制性见解，并提示了年龄适应性治疗策略的潜在靶点。

CORT 沉默损害迁移和侵袭：基于糖基化的风险模型（CORT/LPAR5/CEBPA/MYH10/MAGEA11）在骨肉瘤中的验证

CORT silencing impairs migration and invasion: validation of a glycosylation-based risk model (CORT/LPAR5/CEBPA/MYH10/MAGEA11) in osteosarcoma.

我们开发了一个有用的风险模型，本研究为 OS 治疗提供了新的见解。